Sign in

    Robert Hazlett

    Managing Director/Partner and Senior Equity Research Analyst at BTIG

    Robert Hazlett is a Managing Director/Partner and Senior Equity Research Analyst at BTIG, specializing in the biotechnology and biopharmaceutical sectors with a focus on companies in oncology, central nervous system (CNS), and anti-infective therapeutics. Throughout his career, he has provided research coverage for a wide range of biotechnology companies, including both large-cap and emerging firms, and was recognized as a top stock picker in the biotechnology sector by Thomson Reuters’ StarMine Analyst Awards in 2015. Hazlett joined BTIG in 2016 following roles at Ladenburg Thalmann, Roth Capital Partners, BMO Capital Markets, SunTrust Robinson Humphrey, Lehman Brothers, and UBS, building a track record of strategic insights and investment recommendations. He holds a BA from Yale University and an MBA from Columbia University, further supported by his significant advisory contributions and FINRA securities licenses.

    Robert Hazlett's questions to RedHill Biopharma (RDHL) leadership

    Robert Hazlett's questions to RedHill Biopharma (RDHL) leadership • Q3 2021

    Question

    Robert Hazlett of BTIG asked for anecdotal evidence regarding the sales force's traction with Talicia and whether the market for diagnosing H. pylori was improving. He also requested a revenue breakdown between Movantik and Talicia for the quarter.

    Answer

    SVP of Sales and Marketing Rob Jackson confirmed that field traction for Talicia is improving, with better execution and more consistent growth, and noted that diagnostic conditions have improved since the peak of the pandemic. CFO Micha Ben-Chorin provided the revenue breakdown, stating that Movantik contributed a little over $19 million and Talicia contributed almost $2.25 million in the quarter.

    Ask Fintool Equity Research AI

    Robert Hazlett's questions to RedHill Biopharma (RDHL) leadership • Q2 2021

    Question

    Robert Hazlett asked if the upcoming opaganib Phase 2/3 results could lead to an Emergency Use Authorization (EUA), questioned its manufacturing status, inquired about the I-SPY trial data timeline, the reason for increased R&D spending, and future investment in the prostate cancer program.

    Answer

    COO Gilead Raday stated that the opaganib data will determine the regulatory path, including a potential EUA, and that scaled-up manufacturing is being prepared. CEO Dror Ben-Asher noted it's too early for an I-SPY timeline but expects rapid enrollment. CFO Micha Ben-Chorin attributed higher R&D spend to COVID-19 and NTM programs. COO Gilead Raday confirmed continued development of opaganib in oncology pending full data.

    Ask Fintool Equity Research AI